How to buy Aurinia Pharmaceuticals shares

Aurinia Pharmaceuticals Inc is a biotechnology business with stocks listed in the US. Aurinia Pharmaceuticals shares (AUPH) are listed on the NASDAQ and all prices are listed in US Dollars.

How to buy shares in Aurinia Pharmaceuticals

1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
3. Search for Aurinia Pharmaceuticals. Find the share by name or ticker symbol: AUPH. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Aurinia Pharmaceuticals reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Aurinia Pharmaceuticals, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Aurinia Pharmaceuticals. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Aurinia Pharmaceuticals share price

Use our graph to track the performance of AUPH stocks over time.

Aurinia Pharmaceuticals shares at a glance

• Key figures

Information last updated 2020-09-25.

52-week range	USD$3.52 - USD$21.93
50-day moving average	USD$14.3754
200-day moving average	USD$15.0362
Target price	USD$11.5
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-0.697

Get $0 brokerage on US stocks with trades as little as $50 when you join the world’s biggest social trading network.

eToro Share Trading (US stocks)

USD 0

Standard brokerage - US shares

Get $0 brokerage on US stocks with trades as little as $50 when you join the world’s biggest social trading network.

• $0 brokerage for US stocks
• Trades starting from $50
• Fractional shares
• Copy top traders

Go to site

More info

Important: Share trading carries risk of capital loss.

Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Aurinia Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Aurinia Pharmaceuticals Inc by TradingView

Aurinia Pharmaceuticals financials

Revenue TTM	US$318,000
Gross profit TTM	US$-52,548,000
Return on assets TTM	-27.23%
Return on equity TTM	-77.6%
Profit margin	0%
Book value	2.121
Market capitalisation	US$1.8 billion

TTM: trailing 12 months

Shorting Aurinia Pharmaceuticals shares

There are currently 4.4 million Aurinia Pharmaceuticals shares held short by investors – that's known as Aurinia Pharmaceuticals's "short interest". This figure is 6.1% up from 4.1 million last month.

There are a few different ways that this level of interest in shorting Aurinia Pharmaceuticals shares can be evaluated.

Aurinia Pharmaceuticals's "short interest ratio" (SIR)

Aurinia Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Aurinia Pharmaceuticals shares currently shorted divided by the average quantity of Aurinia Pharmaceuticals shares traded daily (recently around 1.2 million). Aurinia Pharmaceuticals's SIR currently stands at 3.64. In other words for every 100,000 Aurinia Pharmaceuticals shares traded daily on the market, roughly 3640 shares are currently held short.

However Aurinia Pharmaceuticals's short interest can also be evaluated against the total number of Aurinia Pharmaceuticals shares, or, against the total number of tradable Aurinia Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aurinia Pharmaceuticals's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Aurinia Pharmaceuticals shares in existence, roughly 30 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Aurinia Pharmaceuticals shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aurinia Pharmaceuticals.

Find out more about how you can short Aurinia Pharmaceuticals stock.

Aurinia Pharmaceuticals share dividends

We're not expecting Aurinia Pharmaceuticals to pay a dividend over the next 12 months.

Have Aurinia Pharmaceuticals's shares ever split?

Aurinia Pharmaceuticals's shares were split on a 1:50 basis on 22 October 2013. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aurinia Pharmaceuticals shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for Aurinia Pharmaceuticals shares which in turn could have impacted Aurinia Pharmaceuticals's share price.

Aurinia Pharmaceuticals share price volatility

Over the last 12 months, Aurinia Pharmaceuticals's shares have ranged in value from as little as US$3.52 up to US$21.93. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aurinia Pharmaceuticals's is 0.9797. This would suggest that Aurinia Pharmaceuticals's shares are less volatile than average (for this exchange).

Aurinia Pharmaceuticals overview

Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. The company is headquartered in Victoria, Canada.

Frequently asked questions

• What percentage of Aurinia Pharmaceuticals is owned by insiders or institutions?

  Currently 17.108% of Aurinia Pharmaceuticals shares are held by insiders and 49.677% by institutions.

• When does the fiscal year end for Aurinia Pharmaceuticals?

  Aurinia Pharmaceuticals's fiscal year ends in December.

• Where is Aurinia Pharmaceuticals based?

  Aurinia Pharmaceuticals's address is: 4464 Markham Street, Victoria, BC, Canada, V8Z 7X8

• What is Aurinia Pharmaceuticals's ISIN number?

  Aurinia Pharmaceuticals's international securities identification number is: US05156V1026

• What is Aurinia Pharmaceuticals's CUSIP number?

  Aurinia Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 05156V102